223 related articles for article (PubMed ID: 20608285)
1. Control of immediate precursor used in the illicit manufacture of fentanyl as a schedule II controlled substance. Final rule.
Drug Enforcement Administration (DEA), Department of Justice
Fed Regist; 2010 Jun; 75(124):37295-9. PubMed ID: 20608285
[TBL] [Abstract][Full Text] [Related]
2. Control of a chemical precursor used in the illicit manufacture of fentanyl as a List I chemical. Final rule.
Drug Enforcement Administration (DEA), Department of Justice
Fed Regist; 2008 Jul; 73(144):43355-7. PubMed ID: 18949877
[TBL] [Abstract][Full Text] [Related]
3. Control of a chemical precursor used in the illicit manufacture of fentanyl as a List I chemical. Interim rule with request for comments.
Drug Enforcement Administration (DEA), U.S. Department of Justice
Fed Regist; 2007 Apr; 72(77):20039-47. PubMed ID: 17520757
[TBL] [Abstract][Full Text] [Related]
4. Designation of oripavine as a basic class of controlled substance. Final rule.
Drug Enforcement Administration (DEA), Justice
Fed Regist; 2007 Sep; 72(184):54208-10. PubMed ID: 17912784
[TBL] [Abstract][Full Text] [Related]
5. Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-benzylpiperazine into Schedule I of the Controlled Substances Act. Final rule.
Drug Enforcement Administration (DEA), Department of Justice
Fed Regist; 2004 Mar; 69(53):12794-7. PubMed ID: 15029891
[TBL] [Abstract][Full Text] [Related]
6. Schedules of controlled substances: rescheduling of the Food and Drug Administration approved product containing synthetic dronabinol [(-) - [DELTA] less than 9 greater than - (trans)-tetrahydrocannabinol] in sesame oil and encapsulated in soft gelatin capsules from schedule II to schedule III. Department of Justice (DOJ), Drug Enforcement Administration (DEA). Final rule.
Fed Regist; 1999 Jul; 64(127):35928-30. PubMed ID: 10558581
[TBL] [Abstract][Full Text] [Related]
7. Schedules of controlled substances: placement of Zopiclone into schedule IV. Final rule.
Drug Enforcement Administration, Department of Justice
Fed Regist; 2005 Apr; 70(63):16935-7. PubMed ID: 15806735
[TBL] [Abstract][Full Text] [Related]
8. Issuance of multiple prescriptions for schedule II controlled substances. Final rule.
Drug Enforcement Administration (DEA), Department of Justice
Fed Regist; 2007 Nov; 72(222):64921-30. PubMed ID: 18038486
[TBL] [Abstract][Full Text] [Related]
9. Schedules of controlled substances: placement of lisdexamfetamine into schedule II. Final rule.
Drug Enforcement Administration, Department of Justice
Fed Regist; 2007 May; 72(85):24532-4. PubMed ID: 17520775
[TBL] [Abstract][Full Text] [Related]
10. Schedules of controlled substances: placement of 5-methoxy-N,N-dimethyltryptamine into Schedule I of the Controlled Substances Act. Final rule.
Drug Enforcement Administration (DEA), Department of Justice
Fed Regist; 2010 Dec; 75(243):79296-300. PubMed ID: 21171485
[TBL] [Abstract][Full Text] [Related]
11. Control of red phosphorus, white phosphorus and hypophosphorous acid (and its salts) as list I chemicals; exclusions and waivers. Final rule.
Drug Enforcement Administration (DEA), Justice
Fed Regist; 2003 Jun; 68(121):37411-4. PubMed ID: 12836650
[TBL] [Abstract][Full Text] [Related]
12. Schedule of controlled substances: placement of dichloralphenazone into Schedule IV. Final rule.
Drug Enforcement Administration (DEA), Department of Justice
Fed Regist; 2001 Aug; 66(159):42943-4. PubMed ID: 11794309
[TBL] [Abstract][Full Text] [Related]
13. Schedules of controlled substances: placement of tapentadol into schedule II. Final rule.
Drug Enforcement Administration, Department of Justice
Fed Regist; 2009 May; 74(97):23790-3. PubMed ID: 19507329
[TBL] [Abstract][Full Text] [Related]
14. Schedules of controlled substances: placement of pregabalin into schedule V. Final rule.
Drug Enforcement Administration, Department of Justice
Fed Regist; 2005 Jul; 70(144):43633-5. PubMed ID: 16050051
[TBL] [Abstract][Full Text] [Related]
15. Schedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Final rule.
Drug Enforcement Administration (DEA), Department of Justice
Fed Regist; 2004 Sep; 69(188):58950-3. PubMed ID: 15455477
[TBL] [Abstract][Full Text] [Related]
16. Schedules of controlled substances: temporary placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into Schedule I. Final rule.
Drug Enforcement Administration (DEA), Department of Justice
Fed Regist; 2003 Apr; 68(65):16427-30. PubMed ID: 12678045
[TBL] [Abstract][Full Text] [Related]
17. Definition of "positional isomer" as it pertains to the control of schedule I controlled substances. Final rule.
Drug Enforcement Administration (DEA), Department of Justice
Fed Regist; 2007 Dec; 72(231):67850-2. PubMed ID: 18064769
[TBL] [Abstract][Full Text] [Related]
18. Schedules of controlled substances: rescheduling of buprenorphine from schedule V to schedule III. Final rule.
Drug Enforcement Administration (DEA), Department of Justice
Fed Regist; 2002 Oct; 67(194):62354-70. PubMed ID: 12369590
[TBL] [Abstract][Full Text] [Related]
19. Placement of gamma-butyrolactone in List I of the Controlled Substances Act (21 U.S.C. 802(34)). Drug Enforcement Administration, Justice. Final rule.
Fed Regist; 2000 Apr; 65(79):21645-7. PubMed ID: 11010670
[TBL] [Abstract][Full Text] [Related]
20. Schedules of controlled substances: placement of lacosamide into schedule V. Final rule.
Drug Enforcement Administration (DEA), Department of Justice
Fed Regist; 2009 May; 74(97):23789-90. PubMed ID: 19507328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
